Cargando…
Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer
The discovery of homologous recombination deficiency (HRD) biomarkers in prostate cancer is important for patients who will benefit from poly ADP-ribose polymerase inhibitor (PARPi). Here, we developed a transcriptional homologous recombination defectiveness (HRDness) signature, comprising 16 gene p...
Autores principales: | Li, Yawei, Zhao, Zhangxiang, Ai, Liqiang, Wang, Yuquan, Liu, Kaidong, Chen, Bo, Chen, Tingting, Zhuang, Shuping, Xu, Huanhuan, Zou, Min, Gu, Yunyan, Li, Xia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482486/ https://www.ncbi.nlm.nih.gov/pubmed/34622176 http://dx.doi.org/10.1016/j.isci.2021.103135 |
Ejemplares similares
-
A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level
por: Zhuang, Shuping, et al.
Publicado: (2021) -
A genetic map of the chromatin regulators to drug response in cancer cells
por: Chen, Bo, et al.
Publicado: (2022) -
Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome
por: Dong, Qi, et al.
Publicado: (2021) -
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
por: Liu, Kaidong, et al.
Publicado: (2022) -
Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells
por: Liu, Mingyue, et al.
Publicado: (2023)